Recapitulating In Vivo Pharmacokinetics and Size-Dependent Nanomedicine Delivery in a Microfluidic Platform

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Pharmacokinetics

Background:

• Conventional in vitro models inadequately represent the complex pharmacokinetics governing nanomedicine delivery.
• Accurate prediction of nanomedicine therapeutic performance is hindered by the inability of current models to capture dynamic circulation, clearance, and tumor transport.
• Understanding systemic exposure and tumor microenvironment interactions is crucial for nanomedicine development.

Purpose of the Study:

• To develop and validate a microfluidic tumor platform that recapitulates in vivo pharmacokinetic behavior and nanoparticle delivery.
• To establish a predictive framework for evaluating nanomedicine performance by linking systemic pharmacokinetics with tumor-level transport and response.
• To assess the influence of pharmacokinetic exposure and nanoparticle size on intratumoral accumulation and therapeutic efficacy.

Main Methods:

• Development of a microfluidic platform integrating time-resolved concentration control, a vascular barrier, and 3D tumor spheroids.
• Emulation of simultaneous systemic exposure and tumor microenvironment conditions.
• Utilizing paclitaxel-loaded polymeric micelles in a non-small cell lung cancer model to evaluate platform performance.

Main Results:

• The platform successfully reproduced in vivo-like concentration-time profiles and formulation-dependent therapeutic responses.
• Intratumoral accumulation and antitumor efficacy were demonstrated to be dependent on pharmacokinetic exposure and nanoparticle size.
• Size-dependent nanoparticle delivery patterns, including enhanced permeability and retention, were captured by the system.
• The platform linked systemic pharmacokinetics with tumor-level transport and response, aligning with in vivo observations.

Conclusions:

• The developed microfluidic tumor platform provides a more accurate in vitro model for predicting nanomedicine pharmacokinetics and efficacy.
• This system overcomes limitations of conventional assays by integrating dynamic pharmacokinetic parameters and tumor microenvironment simulation.
• The platform establishes a valuable predictive framework for advancing nanomedicine development and personalized cancer therapy.